title: [Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]].
authors.forename: Thomas
authors.initials: T
authors.lastname: Luger
authors.forename: Michael
authors.initials: M
authors.lastname: Reusch
authors.forename: Kristian
authors.initials: K
authors.lastname: Reich
authors.forename: Matthias
authors.initials: M
authors.lastname: Augustin
authors.forename: Wolfram
authors.initials: W
authors.lastname: Sterry
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003880:Dermatology / Q000592:standards*; D005858:Germany; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy / Q000209:etiology; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000188:drug therapy; D012955:Societies, Medical
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab